Your browser doesn't support javascript.
loading
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
Papeix, Caroline; Mazoyer, Julie; Maillart, Elisabeth; Bensa, Caroline; Dubessy, Anne-Laure; Goujon, Catherine; Launay, Odile; Lebrun-Frénay, Christine; Louapre, Céline; Mrejen, Serge; Pourcher, Valérie; Rosenheim, Michel; Stankoff, Bruno; Vidal, Jean-Sebastien; Lubetzki, Catherine.
Afiliación
  • Papeix C; Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
  • Mazoyer J; Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
  • Maillart E; Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
  • Bensa C; Department of Neurology, FONDATION ADOLPHE DE Rothschild, Paris, France.
  • Dubessy AL; Department of Neurology, saint ANTOINE Hospital, APHP-6, Sorbonne University, Paris, France.
  • Goujon C; Pasteur Institute (Medical Center), Paris, France.
  • Launay O; CIC Cochin-Pasteur, APHP 5, Sorbonne Paris Cité, INSERM CIC1417, Paris, France.
  • Lebrun-Frénay C; Department of Neurology, Pasteur 2 hospital, Nice Côte d'Azur University, URRIS UR2 CA, CRCSEP, Nice, France.
  • Louapre C; Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
  • Mrejen S; Department of Neurology, Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France/ Department of Neurology, Robert Ballanger, Aulnay Sous Bois, France.
  • Pourcher V; Infectious Diseases Department, Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, INSERM UMR S 1136, Paris, France.
  • Rosenheim M; Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
  • Stankoff B; Department of Neurology, saint ANTOINE Hospital, APHP-6, Sorbonne University, Paris, France.
  • Vidal JS; Assistance Publique- HOPITAUX de Paris, HOPITAUX Universitaires Paris, Hospital Broca, Service de GERIATRIE, Paris/EA 4468, University of Paris, Paris, France.
  • Lubetzki C; Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
Mult Scler ; 27(14): 2280-2283, 2021 12.
Article en En | MEDLINE | ID: mdl-33870792
BACKGROUND: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. OBJECTIVE: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. METHODS: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. RESULTS: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) (p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53-3.30, p = 0.54). CONCLUSION: These results suggest that YFV does not worsen the course of RR-MS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fiebre Amarilla / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fiebre Amarilla / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Francia